In a strategic move to strengthen its neurology pipeline, Merck KGaA has entered into a research and development collaboration with Valo Health worth up to US$3 B. The agreement grants Merck access to Valo’s AI-driven human data platform and closed-loop chemistry system to accelerate the discovery of novel therapies for Parkinson’s disease and other neurodegenerative disorders. By leveraging Valo’s advanced technology for target identification and small-molecule optimisation, Merck aims to reduce early-stage risk and improve success rates in complex neurological diseases. This partnership reinforces Merck’s commitment to digital innovation and positions the company to regain momentum following recent pipeline setbacks.